Nothing Special   »   [go: up one dir, main page]

SG11201406974YA - Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus - Google Patents

Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Info

Publication number
SG11201406974YA
SG11201406974YA SG11201406974YA SG11201406974YA SG11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA SG 11201406974Y A SG11201406974Y A SG 11201406974YA
Authority
SG
Singapore
Prior art keywords
fusion proteins
vaccinia virus
cells infected
immunoglobulin gene
recombinant vaccinia
Prior art date
Application number
SG11201406974YA
Inventor
Ernest S Smith
Tracy Pandina
Leslie A Croy
Mark Paris
Maurice Zauderer
Angelika Moksa
Renee Kirk
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of SG11201406974YA publication Critical patent/SG11201406974YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201406974YA 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus SG11201406974YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Publications (1)

Publication Number Publication Date
SG11201406974YA true SG11201406974YA (en) 2014-11-27

Family

ID=49477810

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406974YA SG11201406974YA (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Country Status (16)

Country Link
US (3) US9708601B2 (en)
EP (1) EP2841606B1 (en)
JP (2) JP6498599B2 (en)
KR (1) KR102108589B1 (en)
CN (1) CN104520444B (en)
AU (1) AU2013251371B2 (en)
CA (1) CA2871597C (en)
DK (1) DK2841606T3 (en)
EA (1) EA028164B1 (en)
ES (1) ES2725673T3 (en)
IL (1) IL235323B (en)
NZ (1) NZ630854A (en)
PL (1) PL2841606T3 (en)
PT (1) PT2841606T (en)
SG (1) SG11201406974YA (en)
WO (1) WO2013163602A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427212T3 (en) 2009-05-08 2018-02-28 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
PT2766093T (en) 2011-10-11 2018-05-18 Vaccinex Inc Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN105492016A (en) 2013-06-25 2016-04-13 瓦西尼斯公司 Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR20170041167A (en) * 2014-02-19 2017-04-14 조디 베리 Marburg monoclonal antibodies
KR20170019080A (en) 2015-08-11 2017-02-21 주식회사 엘티전자 Flexible Signage Aapparatus
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
CA3018990A1 (en) * 2016-04-22 2017-10-26 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (en) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 Improved Methods for Producing Polynucleotide Libraries in Vaccinia Virus/Eukaryotic Cells
MX2019013110A (en) 2017-05-05 2019-12-16 Vaccinex Inc Human anti-semaphorin 4d antibody.
IL297578A (en) 2020-05-06 2022-12-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
AU2023283554A1 (en) 2022-06-10 2024-12-19 Vaccinex, Inc. Methods to select antibodies specific to complex membrane antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
DK0758397T3 (en) 1994-04-29 2005-10-10 Baxter Healthcare Sa Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2000028016A1 (en) 1998-11-10 2000-05-18 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
AU2001252998A1 (en) 2000-03-28 2001-10-08 University Of Rochester Methods of producing a library and methods of selecting polynucletides
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
ATE352040T1 (en) * 2000-11-17 2007-02-15 Univ Rochester IN-VITRO METHOD FOR PRODUCING AND IDENTIFYING IMMUNOGLOBULIN MOLECULES IN EUKARYOTIC CELLS
AU2002255495A1 (en) 2001-02-02 2002-08-19 University Of Rochester Methods of identifying regulator molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
NZ547591A (en) 2003-12-04 2009-11-27 Vaccinex Inc Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
KR20120116511A (en) 2004-08-27 2012-10-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 Ceramide derivatives as modulators of immunity and autoimmunity
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
US8637026B2 (en) 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
EP2303312B1 (en) 2008-05-28 2016-03-30 Inovio Pharmaceuticals, Inc. Smallpox dna vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
PT2385980T (en) 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PL2427212T3 (en) 2009-05-08 2018-02-28 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
SG10201501767VA (en) * 2010-03-10 2015-05-28 Genmab As Monoclonal antibodies against c-met
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
NZ603193A (en) * 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
MX2012013068A (en) * 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies.
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
JP2013533746A (en) * 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ, インコーポレイテッド Anti-RON antibody
WO2012006342A2 (en) 2010-07-07 2012-01-12 Albert Einstein College Of Medicine Of Yeshiva University Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
JP5925768B2 (en) 2011-05-13 2016-05-25 国立大学法人 東京医科歯科大学 Bone formation promoter
PT2766093T (en) 2011-10-11 2018-05-18 Vaccinex Inc Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9890213B2 (en) 2012-03-02 2018-02-13 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR102176962B1 (en) 2013-01-31 2020-11-10 백시넥스 인코포레이티드 Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CN105492016A (en) 2013-06-25 2016-04-13 瓦西尼斯公司 Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CA3018990A1 (en) 2016-04-22 2017-10-26 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (en) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 Improved Methods for Producing Polynucleotide Libraries in Vaccinia Virus/Eukaryotic Cells
MX2019009986A (en) 2017-02-22 2019-10-14 Vaccinex Inc Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases.
ES2963046T3 (en) 2017-03-20 2024-03-25 Vaccinex Inc Cancer treatment with an anti-semaphorin-4d antibody combined with an epigenetic modulating agent
MX2019013110A (en) 2017-05-05 2019-12-16 Vaccinex Inc Human anti-semaphorin 4d antibody.

Also Published As

Publication number Publication date
KR20150009560A (en) 2015-01-26
EP2841606B1 (en) 2019-01-23
EA201491965A1 (en) 2015-03-31
NZ630854A (en) 2017-03-31
US9708601B2 (en) 2017-07-18
DK2841606T3 (en) 2019-05-06
PT2841606T (en) 2019-05-17
ES2725673T3 (en) 2019-09-26
JP6498599B2 (en) 2019-04-10
CA2871597A1 (en) 2013-10-31
WO2013163602A1 (en) 2013-10-31
US20170306318A1 (en) 2017-10-26
JP2015514811A (en) 2015-05-21
CN104520444B (en) 2017-12-12
US9701958B2 (en) 2017-07-11
JP2019055956A (en) 2019-04-11
KR102108589B1 (en) 2020-05-07
US10662422B2 (en) 2020-05-26
US20160152971A1 (en) 2016-06-02
EP2841606A1 (en) 2015-03-04
CN104520444A (en) 2015-04-15
PL2841606T3 (en) 2019-07-31
AU2013251371A1 (en) 2014-11-13
US20130288927A1 (en) 2013-10-31
IL235323B (en) 2020-01-30
CA2871597C (en) 2021-04-20
AU2013251371B2 (en) 2018-01-04
EP2841606A4 (en) 2015-12-30
IL235323A0 (en) 2014-12-31
EA028164B1 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
IL235323A0 (en) Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
HRP20190574T1 (en) Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
IL285015A (en) Recombinant cell surface capture proteins
PT3744835T (en) Dna modifying fusion proteins and methods of use thereof
HK1209439A1 (en) Interleukin-10 fusion proteins and uses thereof -10
EP2928924A4 (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use
BR112014024675A8 (en) recombinant host cell, cell culture
HK1198446A1 (en) Anti-vegf single variable domains fused to fc domains fc vegf
PT2858490T (en) Recombinant dna elements for the expression of recombinant proteins in insects
BR112013029769A2 (en) recombinant yeast
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
HK1207120A1 (en) Improved harvest operations for recombinant proteins
SG10201507721SA (en) CHO-GMT Recombinant Protein Expression
EP2687537A4 (en) Polypeptide drug against hepatitis b virus x protein
HK1211952A1 (en) Recombinant protein
ZA201504817B (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use
AU2012902684A0 (en) Recombinant Viral Vectors and Uses Therefor
AU2011901988A0 (en) Recombinant viral vaccines